{"entities":[{"id":"aib-doc-generate-prospectus-2026","name":"Generate Biomedicines, Inc. IPO prospectus (424B4)","type":"document","subtype":"Prospectus","description":"SEC 424B4, prospectus dated 26 February 2026, filed 27 February 2026. The cover carries the date February 26, 2026; the EDGAR filing list gives 2026-02-27.","sourceIds":["source-aib-companies-gen-424b4"]}],"claims":[{"id":"aib-co-generate-amgen-novartis-2026","subject":"aib-doc-generate-prospectus-2026","predicate":"states_provision","object":{"kind":"literal","value":"collaborations as stated: Amgen (December 2021; $50.0 million upfront received January 2022) and Novartis (September 2024; $50.0 million upfront received October 2024)"},"topic":"institutions","statement":"Generate Biomedicines' IPO prospectus (26 February 2026) states that it entered a collaboration and license agreement with Amgen in December 2021, receiving a $50.0 million upfront payment in January 2022, and one with Novartis in September 2024, receiving a $50.0 million upfront payment in October 2024.","time":{"kind":"event","date":"2026-02-26","basis":"publication","note":"Dated by the prospectus; the agreement months and receipt months are the company's statements within it."},"resolution":"supported","evidenceIds":["evidence-aib-co-generate-amgen-novartis-2026-1","evidence-aib-co-generate-amgen-novartis-2026-2"],"attributes":{"provision":{"kind":"statement","key":"co-generate-amgen-novartis-2026"}}},{"id":"aib-co-generate-chroma-2026","subject":"aib-doc-generate-prospectus-2026","predicate":"states_provision","object":{"kind":"literal","value":"platform description: generative and predictive models, including diffusion-based models such as Chroma"},"topic":"institutions","statement":"Generate Biomedicines' IPO prospectus (26 February 2026) describes the Generate Platform as integrating generative and predictive models, including \"diffusion-based models (such as our Chroma model)\", with experimental systems.","time":{"kind":"event","date":"2026-02-26","basis":"publication","note":"Prospectus date."},"resolution":"supported","evidenceIds":["evidence-aib-co-generate-chroma-2026-1"],"attributes":{"provision":{"kind":"statement","key":"co-generate-chroma-2026"}}},{"id":"aib-co-generate-gb0895-phase3-2026","subject":"aib-doc-generate-prospectus-2026","predicate":"states_provision","object":{"kind":"literal","value":"company statement: GB-0895 in two Phase 3 trials for severe asthma; first patient dosed 26 January 2026"},"topic":"institutions","statement":"Generate Biomedicines' IPO prospectus (26 February 2026) states that it was enrolling patients in two Phase 3 clinical trials of GB-0895 for severe asthma, initiated in December 2025, and that \"the first patient was dosed\" in the SOLAIRIA-1 Phase 3 trial on 26 January 2026.","time":{"kind":"event","date":"2026-02-26","basis":"publication","note":"Dated by the prospectus that states it; the dosing date (2026-01-26) and initiation month (December 2025) are the company's statements within it."},"resolution":"supported","evidenceIds":["evidence-aib-co-generate-gb0895-phase3-2026-1","evidence-aib-co-generate-gb0895-phase3-2026-2"],"attributes":{"provision":{"kind":"statement","key":"co-generate-gb0895-phase3-2026"}}},{"id":"aib-co-generate-information-science-2026","subject":"aib-doc-generate-prospectus-2026","predicate":"states_provision","object":{"kind":"literal","value":"framing statement: \"Biology is an information science.\""},"topic":"institutions","statement":"Generate Biomedicines' IPO prospectus (26 February 2026) states that \"Biology is an information science\" and that DNA's encoding of function \"in principle, makes biology programmable\".","time":{"kind":"event","date":"2026-02-26","basis":"publication","note":"Prospectus date."},"resolution":"supported","evidenceIds":["evidence-aib-co-generate-information-science-2026-1"],"attributes":{"provision":{"kind":"statement","key":"co-generate-information-science-2026"}}},{"id":"aib-co-generate-ipo-2026","subject":"aib-doc-generate-prospectus-2026","predicate":"states_provision","object":{"kind":"literal","value":"initial public offering: 25,000,000 shares at $16.00; Nasdaq symbol GENB"},"topic":"institutions","statement":"Generate Biomedicines' prospectus dated 26 February 2026 states an initial public offering of 25,000,000 shares of common stock at $16.00 per share, approved for listing on the Nasdaq Global Select Market under the symbol GENB.","time":{"kind":"event","date":"2026-02-26","basis":"publication","note":"Prospectus date; the prospectus states that the underwriters expect to deliver the shares on or about March 2, 2026."},"resolution":"supported","evidenceIds":["evidence-aib-co-generate-ipo-2026-1","evidence-aib-co-generate-ipo-2026-2"],"attributes":{"provision":{"kind":"statement","key":"co-generate-ipo-2026"}}}],"sources":[{"id":"source-aib-companies-gen-424b4","documentId":"aib-doc-generate-prospectus-2026","title":"Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock","authors":["Generate Biomedicines, Inc. (filed with the US SEC)"],"publisher":"Generate Biomedicines, Inc. (filed with the US SEC)","publisherId":"aib-generate-biomedicines","publicationDate":"2026-02-26","version":"Retrieved for the candidate pack on 2026-10-30 (SHA-256 ca57aeb45111477c90d801e907d1999257ae15cc1ed3901b6317a77907c83d37). SEC EDGAR 424B4, accession 0001193125-26-083190, filed 2026-02-27; prospectus dated February 26, 2026; as served on 2026-10-30.","evidenceUrl":"https://www.sec.gov/Archives/edgar/data/2100782/000119312526083190/generate_bio_424b4.htm","language":"en"}],"evidence":[{"id":"evidence-aib-co-generate-amgen-novartis-2026-1","claimId":"aib-co-generate-amgen-novartis-2026","sourceId":"source-aib-companies-gen-424b4","support":"supports","locator":"Risk factors, paragraph beginning \"To date, we have financed our operations\" (prospectus p. 19)","passage":"In December 2021, we entered into a collaboration and license agreement with Amgen, as amended (as amended from time to time, the “Amgen Collaboration Agreement”), and, in connection therewith, we received a non-refundable upfront payment of $50.0 million in January 2022","passageType":"quote"},{"id":"evidence-aib-co-generate-chroma-2026-1","claimId":"aib-co-generate-chroma-2026","sourceId":"source-aib-companies-gen-424b4","support":"supports","locator":"Prospectus summary, \"The Generate Platform\"","passage":"The Generate Platform integrates generative and predictive models that learn design principles from proprietary data—e.g., diffusion-based models (such as our Chroma model) and graph neural networks, among other architectures","passageType":"quote"},{"id":"evidence-aib-co-generate-gb0895-phase3-2026-1","claimId":"aib-co-generate-gb0895-phase3-2026","sourceId":"source-aib-companies-gen-424b4","support":"supports","locator":"Prospectus summary, \"Overview\"","passage":"We are currently enrolling patients in two parallel global Phase 3 clinical trials for GB-0895 initiated in December 2025 (SOLAIRIA-1 and SOLAIRIA-2) for severe asthma, with full enrollment expected by the first half of 2028.","passageType":"quote"},{"id":"evidence-aib-co-generate-information-science-2026-1","claimId":"aib-co-generate-information-science-2026","sourceId":"source-aib-companies-gen-424b4","support":"supports","locator":"Prospectus summary, \"Overview\"","passage":"Biology is an information science. DNA encodes biological function through the way its sequence determines the structure and activity of the molecules it produces, which, in principle, makes biology programmable.","passageType":"quote"},{"id":"evidence-aib-co-generate-ipo-2026-1","claimId":"aib-co-generate-ipo-2026","sourceId":"source-aib-companies-gen-424b4","support":"supports","locator":"Prospectus cover","passage":"This is the initial public offering of shares of common stock of Generate Biomedicines, Inc. We are offering 25,000,000 shares of our common stock.","passageType":"quote"}],"at":{"entities":[1352],"claims":[3577,3578,3579,3580,3581],"sources":[1145],"evidence":[4943,4945,4946,4948,4949]},"index":{"byClaim":[],"marks":[],"chronicle":{"years":[{"year":1863,"topics":{"ideas":5},"stated":0},{"year":1865,"topics":{"ideas":1},"stated":0},{"year":1872,"topics":{"ideas":7},"stated":0},{"year":1943,"topics":{"ideas":1},"stated":0},{"year":1947,"topics":{"ideas":2},"stated":0},{"year":1950,"topics":{"ideas":7},"stated":0},{"year":1951,"topics":{"ideas":5},"stated":0},{"year":1952,"topics":{"ideas":2},"stated":0},{"year":1955,"topics":{"ideas":31},"stated":0},{"year":1956,"topics":{"ideas":1},"stated":0},{"year":1957,"topics":{"ideas":1},"stated":0},{"year":1958,"topics":{"ideas":3},"stated":0},{"year":1959,"topics":{"ideas":6},"stated":0},{"year":1960,"topics":{"ideas":11},"stated":0},{"year":1961,"topics":{"ideas":10},"stated":0},{"year":1965,"topics":{"ideas":8},"stated":0},{"year":1966,"topics":{"ideas":20},"stated":0},{"year":1968,"topics":{"ideas":5},"stated":0},{"year":1969,"topics":{"ideas":2},"stated":0},{"year":1971,"topics":{"ideas":4},"stated":0},{"year":1972,"topics":{"ideas":1},"stated":0},{"year":1973,"topics":{"ideas":2},"stated":0},{"year":1974,"topics":{"ideas":2},"stated":0},{"year":1975,"topics":{"ideas":1},"stated":0},{"year":1976,"topics":{"ideas":1},"stated":0},{"year":1977,"topics":{"people":2,"ideas":8},"stated":0},{"year":1979,"topics":{"ideas":4},"stated":0},{"year":1980,"topics":{"ideas":2},"stated":0},{"year":1981,"topics":{"people":2},"stated":0},{"year":1982,"topics":{"ideas":4},"stated":0},{"year":1983,"topics":{"ideas":4},"stated":0},{"year":1984,"topics":{"ideas":21},"stated":0},{"year":1985,"topics":{"ideas":9},"stated":0},{"year":1986,"topics":{"ideas":18},"stated":0},{"year":1987,"topics":{"ideas":1},"stated":0},{"year":1988,"topics":{"ideas":6},"stated":0},{"year":1989,"topics":{"ideas":8},"stated":0},{"year":1990,"topics":{"ideas":5},"stated":0},{"year":1991,"topics":{"ideas":11},"stated":0},{"year":1992,"topics":{"ideas":9},"stated":0},{"year":1993,"topics":{"ideas":14,"people":3},"stated":0},{"year":1994,"topics":{"ideas":14},"stated":0},{"year":1995,"topics":{"ideas":10,"people":1},"stated":0},{"year":1996,"topics":{"ideas":71},"stated":0},{"year":1997,"topics":{"ideas":12},"stated":0},{"year":1998,"topics":{"ideas":49},"stated":0},{"year":1999,"topics":{"ideas":27,"people":1,"institutions":1},"stated":0},{"year":2000,"topics":{"ideas":62},"stated":0},{"year":2001,"topics":{"ideas":39},"stated":0},{"year":2002,"topics":{"ideas":30},"stated":0},{"year":2003,"topics":{"ideas":8},"stated":0},{"year":2004,"topics":{"ideas":12,"people":3},"stated":0},{"year":2005,"topics":{"ideas":10,"people":1},"stated":0},{"year":2006,"topics":{"ideas":26,"people":1},"stated":0},{"year":2007,"topics":{"ideas":20},"stated":0},{"year":2008,"topics":{"ideas":57,"people":3,"institutions":1},"stated":0},{"year":2009,"topics":{"ideas":10,"people":1},"stated":0},{"year":2010,"topics":{"people":3,"ideas":11,"institutions":1,"governance":4},"stated":0},{"year":2011,"topics":{"people":3,"ideas":7,"institutions":2},"stated":0},{"year":2012,"topics":{"people":4,"ideas":17,"institutions":2},"stated":0},{"year":2013,"topics":{"ideas":46,"people":4,"institutions":2,"capital":1},"stated":0},{"year":2014,"topics":{"institutions":2,"ideas":54,"people":5},"stated":0},{"year":2015,"topics":{"people":22,"ideas":122,"institutions":3,"capital":1},"stated":0},{"year":2016,"topics":{"ideas":88,"people":2},"stated":0},{"year":2017,"topics":{"people":16,"institutions":2,"ideas":128,"governance":2},"stated":0},{"year":2018,"topics":{"people":8,"ideas":158,"institutions":8,"governance":1},"stated":0},{"year":2019,"topics":{"capital":1,"compute":1,"people":10,"governance":19,"ideas":175,"institutions":4},"stated":0},{"year":2020,"topics":{"people":6,"ideas":98,"institutions":1,"governance":2},"stated":0},{"year":2021,"topics":{"people":27,"ideas":177,"compute":1,"institutions":23,"governance":4,"capital":6},"stated":0},{"year":2022,"topics":{"people":15,"ideas":217,"institutions":6,"governance":3,"compute":2,"capital":1},"stated":0},{"year":2023,"topics":{"capital":5,"compute":7,"institutions":23,"people":51,"governance":179,"ideas":389},"stated":0},{"year":2024,"topics":{"capital":12,"compute":19,"governance":282,"people":80,"ideas":178,"institutions":28},"stated":1},{"year":2025,"topics":{"governance":547,"compute":69,"capital":34,"people":90,"institutions":18,"ideas":178},"stated":7},{"year":2026,"topics":{"governance":442,"capital":8,"compute":32,"institutions":21,"ideas":91,"people":107},"stated":19},{"year":2027,"topics":{},"stated":9},{"year":2028,"topics":{},"stated":6},{"year":2029,"topics":{},"stated":3},{"year":2030,"topics":{},"stated":3},{"year":2032,"topics":{},"stated":2},{"year":2035,"topics":{},"stated":2},{"year":2039,"topics":{},"stated":1},{"year":2042,"topics":{},"stated":1},{"year":2050,"topics":{},"stated":1}],"scheduled":[],"statedBy":[]},"collections":[{"target":{"kind":"propositions","id":"superintelligence"},"title":"Propositions about superintelligence, 1863–2022","claimIds":[],"records":[]},{"target":{"kind":"propositions","id":"risk-debate"},"title":"Arguments about catastrophic risk from advanced AI","claimIds":[],"records":[]},{"target":{"kind":"propositions","id":"yudkowsky-arguments"},"title":"Eliezer Yudkowsky’s arguments on common claims about AI, 1996–2026","claimIds":[],"records":[]},{"target":{"kind":"propositions","id":"economics-of-machine-intelligence"},"title":"Economics of machine intelligence","claimIds":[],"records":[]},{"target":{"kind":"propositions","id":"orbital-compute-arguments"},"title":"Arguments about compute in orbit","claimIds":[],"records":[]},{"target":{"kind":"propositions","id":"ai-bio-arguments"},"title":"Arguments about AI and biological risk","claimIds":[],"records":[]},{"target":{"kind":"propositions","id":"ai-in-science"},"title":"AI in science","claimIds":[],"records":[]},{"target":{"kind":"documents"},"title":"Frontier safety frameworks","claimIds":[]},{"target":{"kind":"compare","id":"frontier-safety-frameworks"},"title":"Compare frameworks","claimIds":[]},{"target":{"kind":"control","id":"openai"},"title":"OpenAI’s control structure, 2015–2026","claimIds":[]},{"target":{"kind":"control","id":"anthropic"},"title":"Anthropic’s control structure, 2021–2026","claimIds":[]},{"target":{"kind":"commitments"},"title":"External commitments and obligations","claimIds":[]},{"target":{"kind":"question","id":"frameworks-to-obligations"},"title":"Frameworks, commitments and legal obligations, 2023–2026","claimIds":[]},{"target":{"kind":"reading"},"title":"Founding and early leadership","claimIds":[]}]},"version":"131evrz"}